[{"id":"2a09abe0-6495-491d-a75a-5fe8da47ac10","acronym":"","url":"https://clinicaltrials.gov/study/NCT04086485","created_at":"2021-01-18T20:00:12.098Z","updated_at":"2025-02-25T12:27:19.621Z","phase":"Phase 1/2","brief_title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","source_id_and_acronym":"NCT04086485","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["BRCA • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-24"},{"id":"2a6d7e4f-c35c-4e6b-8dc6-72106bb36c61","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750954","created_at":"2023-12-06T16:15:46.614Z","updated_at":"2025-02-25T13:53:37.832Z","phase":"Phase 1","brief_title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04750954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-20"},{"id":"fdfd9de7-291d-41f6-a1e7-37009f68c58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665739","created_at":"2021-01-19T20:43:36.156Z","updated_at":"2025-02-25T14:15:45.821Z","phase":"Phase 2","brief_title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","source_id_and_acronym":"NCT04665739","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"4be67477-813c-4d4a-afcc-f5d5c110e3d8","acronym":"ReLUTH","url":"https://clinicaltrials.gov/study/NCT04954820","created_at":"2021-07-08T14:52:46.401Z","updated_at":"2025-02-25T16:45:28.459Z","phase":"Phase 2","brief_title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","source_id_and_acronym":"NCT04954820 - ReLUTH","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/01/2031","primary_completion_date":" 10/01/2031","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2025-02-06"},{"id":"05512785-f9fe-439d-9e0c-f165bade4b72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206060","created_at":"2021-01-18T15:48:09.116Z","updated_at":"2025-02-25T16:44:08.576Z","phase":"Phase 2","brief_title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","source_id_and_acronym":"NCT03206060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • VHL • SSTR","pipe":" | ","alterations":" RET mutation • VHL mutation","tags":["NF1 • VHL • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-05"},{"id":"449ed9d2-cfb9-4804-ab05-1adc2070268b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122610","created_at":"2023-11-08T22:13:11.239Z","updated_at":"2025-02-25T16:47:11.811Z","phase":"Phase 1","brief_title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","source_id_and_acronym":"NCT06122610","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-05"},{"id":"11c83591-4e3f-4858-aa5c-0d9de1fd1c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691465","created_at":"2023-01-20T16:00:13.319Z","updated_at":"2025-02-25T16:54:41.696Z","phase":"Phase 2","brief_title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","source_id_and_acronym":"NCT05691465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • RB1 • SYP • CHGA","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-04"},{"id":"08d03f09-1c0e-4f63-9272-84ef1303882d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04529044","created_at":"2021-01-18T21:41:11.607Z","updated_at":"2025-02-25T15:44:08.465Z","phase":"Phase 2","brief_title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","source_id_and_acronym":"NCT04529044","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1 • CDK4 • SSTR","pipe":"","alterations":" ","tags":["PD-L1 • CDK4 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-12-20"},{"id":"037190b9-a29c-4950-8488-50ec828ead4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609592","created_at":"2021-02-11T16:55:29.685Z","updated_at":"2025-02-25T15:44:13.594Z","phase":"Phase 1","brief_title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","source_id_and_acronym":"NCT04609592","lead_sponsor":"Stanford University","biomarkers":" SSTR","pipe":" | ","alterations":" PGR expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-10-28"},{"id":"0661b272-42c1-4893-b062-503b09cba715","acronym":"NELMAS","url":"https://clinicaltrials.gov/study/NCT05987176","created_at":"2023-08-14T15:10:04.790Z","updated_at":"2025-02-25T15:54:51.896Z","phase":"Phase 2","brief_title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","source_id_and_acronym":"NCT05987176 - NELMAS","lead_sponsor":"Imperial College London","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 08/02/2024","start_date":" 08/02/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 03/30/2029","study_completion_date":" 03/30/2029","last_update_posted":"2024-08-09"},{"id":"470be808-bc58-41ba-9198-bd615bd2748f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04711135","created_at":"2021-02-11T16:55:42.049Z","updated_at":"2024-07-02T16:34:25.979Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","source_id_and_acronym":"NCT04711135","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 03/12/2024","primary_completion_date":" 03/12/2024","study_txt":" Completion: 05/07/2029","study_completion_date":" 05/07/2029","last_update_posted":"2024-06-14"},{"id":"8958a804-5b40-4f07-97d2-e49b0ff21eec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04946305","created_at":"2021-06-30T17:54:27.285Z","updated_at":"2024-07-02T16:34:25.830Z","phase":"","brief_title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","source_id_and_acronym":"NCT04946305","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 07/08/2024","primary_completion_date":" 07/08/2024","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-06-14"},{"id":"2d466bac-cc21-4880-9a02-9ce432c80a1e","acronym":"ETCTN 10388","url":"https://clinicaltrials.gov/study/NCT04234568","created_at":"2023-12-06T21:16:22.996Z","updated_at":"2024-07-02T16:34:26.307Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","source_id_and_acronym":"NCT04234568 - ETCTN 10388","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Triapine (3-AP)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-13"},{"id":"9236ed5b-4e48-4482-beb7-c4a2d4ec1f1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05844332","created_at":"2023-05-06T15:04:24.810Z","updated_at":"2024-07-02T16:34:27.152Z","phase":"","brief_title":"LUTATHERA Injection General Use Result Survey","source_id_and_acronym":"NCT05844332","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 347","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"3860705e-302a-47ca-86d2-2608fd1b0f73","acronym":"","url":"https://clinicaltrials.gov/study/NCT05247905","created_at":"2022-02-21T14:52:59.210Z","updated_at":"2024-07-02T16:35:01.279Z","phase":"Phase 2","brief_title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT05247905","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • capecitabine • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 10/01/2033","study_completion_date":" 10/01/2033","last_update_posted":"2024-05-23"},{"id":"0a7abb08-ccb1-4e69-80bd-9e92b2a533e2","acronym":"NETTER-2","url":"https://clinicaltrials.gov/study/NCT03972488","created_at":"2021-02-11T16:53:55.907Z","updated_at":"2024-07-02T16:35:03.576Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","source_id_and_acronym":"NCT03972488 - NETTER-2","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 10/29/2027","study_completion_date":" 10/29/2027","last_update_posted":"2024-05-15"},{"id":"3dd674e6-b496-4d73-a6b8-026abbece6f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05142696","created_at":"2021-12-02T15:53:46.962Z","updated_at":"2024-07-02T16:35:06.048Z","phase":"Phase 1/2","brief_title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","source_id_and_acronym":"NCT05142696","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • Tevimbra (tislelizumab-jsgr) • etoposide IV • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 05/05/2025","primary_completion_date":" 05/05/2025","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2024-05-03"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"90bc3653-4e66-4df1-bfe9-4abee846b758","acronym":"iPRRT","url":"https://clinicaltrials.gov/study/NCT05583708","created_at":"2022-10-18T14:57:03.428Z","updated_at":"2024-07-02T16:35:09.073Z","phase":"Phase 2","brief_title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","source_id_and_acronym":"NCT05583708 - iPRRT","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-17"},{"id":"0e0834be-0c1a-4cc9-89e5-a3e0950833c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082520","created_at":"2021-02-11T16:54:03.522Z","updated_at":"2024-07-02T16:35:12.274Z","phase":"Phase 2","brief_title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","source_id_and_acronym":"NCT04082520","lead_sponsor":"Mayo Clinic","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2025","study_completion_date":" 09/04/2025","last_update_posted":"2024-03-29"},{"id":"fa4ac16f-1835-4662-8af1-7fcab76575bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06016855","created_at":"2023-08-30T14:08:43.881Z","updated_at":"2024-07-02T16:35:12.390Z","phase":"Phase 4","brief_title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT06016855","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2024-03-28"},{"id":"8e9016c5-f335-427f-9f26-0ca96ab2e497","acronym":"LANTana","url":"https://clinicaltrials.gov/study/NCT05178693","created_at":"2022-01-05T12:53:41.791Z","updated_at":"2025-02-25T15:54:18.184Z","phase":"Phase 1","brief_title":"Lutathera and ASTX727 in Neuroendocrine Tumours","source_id_and_acronym":"NCT05178693 - LANTana","lead_sponsor":"Imperial College London","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"abe95a5f-8246-429d-92a8-a73471011fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01876771","created_at":"2021-01-18T08:24:57.554Z","updated_at":"2024-07-02T16:35:21.860Z","phase":"Phase 2","brief_title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","source_id_and_acronym":"NCT01876771","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/29/2014","start_date":" 04/29/2014","primary_txt":" Primary completion: 12/01/2033","primary_completion_date":" 12/01/2033","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2024-01-30"}]